Otonomy to Participate in Four Upcoming Investor Conferences

Rhea-AI Summary

Otonomy, a biopharmaceutical firm focused on neurotology, will participate in four upcoming virtual investor conferences. Key events include the Citi’s 15th Annual BioPharma Conference on September 9-10, 2020, H.C. Wainwright’s Global Investment Conference on September 14, 2020, Cantor's Virtual Healthcare Conference on September 16, 2020, and the Oppenheimer Fall Healthcare Summit on September 23, 2020. Presentations will be accessible via a live audio webcast on the company's website, emphasizing their innovative therapies aimed at treating unmet medical needs in hearing and balance disorders.

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in four upcoming virtual investor conferences.

• Citi’s 15^th Annual BioPharma Virtual Conference on September 9-10, 2020: 1 on 1 investor meetings.
   
• H.C. Wainwright 22nd Annual Global Investment Conference: presentation on September 14, 2020 at 12 p.m. ET (9 a.m. PT).
   
• Cantor Virtual Global Healthcare Conference: presentation on September 16, 2020 at 9:20 a.m. ET (6:20 a.m. PT).
   
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: presentation on September 23, 2020 at 10 a.m. ET (7 a.m. PT).

A live audio webcast of the presentations will be available through the Events page of the company's website (www.otonomy.com). 

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

When is Otonomy participating in virtual investor conferences?

Otonomy will participate in several virtual investor conferences, including: Citi’s 15th Annual BioPharma Conference on September 9-10, 2020, H.C. Wainwright’s Conference on September 14, 2020, Cantor's Conference on September 16, 2020, and Oppenheimer’s Summit on September 23, 2020.

What is the schedule for Otonomy's presentations in September 2020?

Otonomy's presentation schedule includes: H.C. Wainwright on September 14, 2020 at 12 p.m. ET, Cantor on September 16, 2020 at 9:20 a.m. ET, and Oppenheimer on September 23, 2020 at 10 a.m. ET.

How can investors access Otonomy's presentations?

Investors can access Otonomy's presentations through a live audio webcast available on the company's website.

What does Otonomy focus on in their biopharmaceutical developments?

Otonomy focuses on developing innovative therapeutics for neurotology, particularly addressing conditions like Ménière’s disease, hearing loss, and tinnitus.